Importance: Initial treatment for amblyopia of the fellow eye with patching and atropine sulfate eyedrops improves visual acuity. Long-term data on the durability of treatment benefit are needed.

Objective: To report visual acuity at 15 years of age among patients who were younger than 7 years when enrolled in a treatment trial for moderate amblyopia.

Design, Setting, And Participants: In a multicenter clinical trial, 419 children with amblyopia (visual acuity, 20/40 to 20/100) were randomly assigned to patching (minimum of 6 h/d) or atropine sulfate eyedrops, 1% (1 drop daily), for 6 months. Treatment after 6 months was at the discretion of the investigator. Two years after enrollment, an unselected subgroup of 188 children were enrolled into long-term follow-up.

Intervention: Initial treatment with patching or atropine with subsequent treatment at investigator discretion.

Main Outcomes And Measures: Visual acuity at 15 years of age with the electronic Early Treatment Diabetic Retinopathy Study test in amblyopic and fellow eyes.

Results: Mean visual acuity in the amblyopic eye measured in 147 participants at 15 years of age was 0.14 logMAR (approximately 20/25); 59.9% of amblyopic eyes had visual acuity of 20/25 or better and 33.3%, 20/20 or better. Mean interocular acuity difference (IOD) at 15 years of age was 0.21 logMAR (2.1 lines); 48.3% had an IOD of 2 or more lines and 71.4%, 1 or more lines. Treatment (other than spectacles) was prescribed for 9 participants (6.1%) aged 10 to 15 years. Mean IOD was similar at examinations at 10 and 15 years of age (2.0 and 2.1 logMAR lines, respectively; P = .39). Better visual acuity at the 15-year examination was achieved in those who were younger than 5 years at the time of entry into the randomized clinical trial (mean logMAR, 0.09) compared with those aged 5 to 6 years (mean logMAR, 0.18; P < .001). When we compared subgroups based on original treatment with atropine or patching, no significant differences were observed in visual acuity of amblyopic and fellow eyes at 15 years of age (P = .44 and P = .43, respectively).

Conclusions And Relevance: At 15 years of age, most children treated for moderate amblyopia when younger than 7 years have good visual acuity, although mild residual amblyopia is common. The outcome is similar regardless of initial treatment with atropine or patching. The results indicate that improvement occurring with amblyopia treatment is maintained until at least 15 years of age.

Trial Registration: clinicaltrials.gov Identifier: NCT00000170.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206086PMC
http://dx.doi.org/10.1001/jamaophthalmol.2014.392DOI Listing

Publication Analysis

Top Keywords

visual acuity
28
years age
24
clinical trial
12
years
11
treatment
9
randomized clinical
8
initial treatment
8
patching atropine
8
atropine sulfate
8
sulfate eyedrops
8

Similar Publications

Purpose This study evaluated the efficacy of oral melatonin therapy for visual acuity and retinal and choroidal structures in patients with chronic central serous chorioretinopathy (CSCR). Methods Fourteen patients with CSCR were included; eight received oral melatonin (3 mg nightly), and six formed the control group. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and choroidal vascularity index (CVI) were assessed at baseline and after one month.

View Article and Find Full Text PDF

Optic nerve disorders significantly contribute to visual impairment with irreversible visual deficits. Current treatments have limited efficacy in resolving chronic visual deficits, necessitating novel therapeutic strategies. Neurorehabilitation techniques, including repetitive transorbital alternating current stimulation (rtACS), have emerged as promising approaches to restore lost visual function through the ability to modulate brain activity.

View Article and Find Full Text PDF

Background: Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy.

View Article and Find Full Text PDF

Purpose: Systemic sclerosis (SSc) affects blood vessels, internal organs, and skin. In ophthalmology, SSc impacts the choroid. The choroidal vascularity index (CVI) measures the vascular component of the choroid and may serve as a biomarker for the disease staging and prognosis.

View Article and Find Full Text PDF

Late presentation of Coats disease in a 12-year-old boy: a case report.

Pan Afr Med J

January 2025

Department of Ophthalmology, Faculty of Medicine Universitas Airlangga, Dr Soetomo Hospital, Surabaya, Indonesia.

Coats disease is a rare abnormality characterized with retinal telangiectasia and aneurysms with retinal exudation, most often seen in young males and usually affecting only one eye. A 12-year-old boy came in with a three-month history of vision loss and pain in his right eye, alongside progressively worsening blurred vision over the last year. His visual acuity was reduced to only light perception in the right eye, while his left eye maintained 5/5 vision.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!